TÇTaner Çin

Taner Çin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Taner Çin has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Serum Tau and α‐Synuclein in Children With Attention‐Deficit/Hyperactivity Disorder: Cross‐Sectional Associations With Methylphenidate Treatment

    by Deniz Doğan, Elvan İşEri, Aybeniz Civan Kahve, Samet Can Demirci, Dicle Büyüktaşkın, Ahmet Özaslan, Taner Çin, Esra Kara Aşkın, Önder Aydemir, Özlem Gülbahar, et al.

    Objective: To compare serum total tau and α‐synuclein among controls, drug‐naïve children with attention‐deficit/hyperactivity disorder (ADHD) and children with ADHD receiving methylphenidate. Methods: Original ELISA spreadsheets provided 26 controls, 29 evaluable drug‐naïve participants and 32 methylphenidate‐treated participants. Boundary‐coded results (> 500 pg/mL for tau; < 938 pg/mL for α‐synuclein) were assigned the recorded boundary for rank‐based analyses. Groups were compared using Kruskal–Wallis tests and Dunn–Bonferroni contrasts; within‐group associations used Spearman correlations. Results: α‐Synuclein differed among groups ( H = 49.859, p < 0.001, ε 2 = 0.570), with all pairwise contrasts significant. Tau also differed ( H = 10.492, p = 0.005, ε 2 = 0.101); drug‐naïve ADHD had lower tau than controls, whereas the treated group differed from neither comparator after correction. The α‐synuclein–tau correlation remained significant after false‐discovery‐rate adjustment only in drug‐naïve ADHD ( ρ = 0.443, adjusted p = 0.048). Conclusions: Serum α‐synuclein and total tau showed distinct cross‐sectional group patterns. These associations do not establish methylphenidate effects and require prospective confirmation.

  • Open Access

    Pharmacotherapy of Psychotic Disorders in Türkiye: Insights From a National Prescription Database

    by Sena Türkeş, Aybeniz Civan Kahve, Taner Çin, Esra Şafak Yılmaz, Hakkı Gürsöz, Süreyya Barun

    Objective: Psychotic disorders, affecting 3–7 per 1000 individuals, significantly impair mental functioning. Although antipsychotic medications represent the mainstay of treatment, prescribing practices can vary based on patient characteristics and across different countries. Currently, national epidemiological data on psychotropic prescribing patterns in Türkiye are lacking, and understanding these variations is crucial for informing treatment guidelines and optimizing patient care. Methods: Data from the Turkish Prescription Information System (PIS) for the year 2019 were analyzed to evaluate antipsychotic prescribing patterns for psychotic disorders. Included were prescriptions for schizophrenia, other specified psychotic disorders not attributable to a substance or known physiological condition, and unspecified psychosis with the same exclusion criteria. Results: Second‐generation antipsychotics (SGAs) constituted 80% of all prescriptions, making them the most frequently prescribed class in Türkiye. This finding is consistent with other national studies. Quetiapine was the most frequently prescribed SGA overall, although prescribing patterns varied by age group. Although SGAs were the most commonly prescribed class, typical antipsychotics or first‐generation antipsychotics (FGAs) remained in use, particularly haloperidol in patients aged ≥80 years. Conclusions: This national study demonstrates the widespread use of SGAs in Türkiye, particularly quetiapine, while also highlighting the continued use of FGAs, especially haloperidol, in older adults. These findings highlight the need for further research on age‐specific prescribing practices and the development of tailored treatment guidelines. Furthermore, international comparisons of prescribing patterns should be conducted to identify potential variations and explore their underlying causes.